Tuesday, December 1, 2020
Home Latest Pharma-News

Latest Pharma-News

KarXT enrolled in Phase II clinical trial for the treatment of acute psychosis in schizophrenia patients

Nov 19, 2019: Karuna Therapeutics  announced  that KarXT assured for the treatment of acute psychosis in schizophrenia patient sign up in a...

TWILIGHT trial showed that Brilinta (ticagrelor) monotherapy reduced the risk of clinically relevant bleeding compared to dual antiplatelet therapy (DAPT) in patients with non-ST...

Nov 17, 2019: From subgroup analysis of the TWILIGHT trial in patients with non-ST elevation acute coronary syndromes(NSTE-ACS), Brilinta (ticagrelor) monotherapy reduced the...

Novartis Phase III PARAGON-HF study: Substantial reductions in heart failure with preserved ejection fraction with Entresto

Nov 18, 2019: Novartis Phase III PARAGON-HF study plays a key role for patients with diastolic heart failure with preserved ejection fraction...

Cardiff University’s scientist awarded the funding of £373k to diagnose pancreatic cancer at an earlier stage

Nov 18, 2019: Dr Catherine Hogan at Cardiff University’s European Cancer Stem Cell Research Institute has been awarded the funding of £373k...

SurVaxM: A novel anti-cancer immunotherapy for the treatment of glioblastoma brain cancers

Nov 15, 2019: Shanghai Fosun Pharmaceutical and MimiVax LLC have entered into a China-exclusive licensing agreement for the clinical development and commercialization...

Initiation Of First Large-Scale Registry :To Evaluate Real-World Lipid Management And The Effectiveness Of PCSK9 Inhibitors

Nov. 15, 2019: Amgen and the Duke Clinical Research Institute (DCRI) announced plans to initiate the Cardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9 inhibitors (cvMOBIUS) study in order...

Single, subanesthetic-dose of ketamine infusion relatively free of side effects for patients with treatment-resistant depression

Nov 15, 2019: NIH researchers found that a single, subanesthetic-dose of ketamine infusion was relatively free of side effects...

New Novartis medicine Adakveo® (crizanlizumab) approved by FDA for the treatment of individuals living with sickle cell disease

Nov 15, 2019: FDA approved Novartis's Adakveo (crizanlizumab-tmca) for the treatment to...

BMS and Pfizer to start a new randamized controlled trial accessing the impact of atrial fibrillation screening on health outcomes in older individuals

Nov 16, 2019: PRINCETON, N.J. and Bristol-Myers Squibb-Pfizer Alliance announced the initiation of a new randomized controlled trial (GUARD-AF) for undiagnosed...

FDA approves Talicia To Treat bacterial infection Linked To Stomach Cancer

Nov 16, 2019: Bacterial infection affects millions of American adults in a year and is one of the strongest known causes of...

Zydus Cadila gets tentative approval from USFDA for Apremilast tablets for the treatment of psoriatic arthritis

Nov 16, 2019: USFDA approved Zydus Cadila’s Apremilast tablets for the treatment of psoriatic arthritis and moderate to severe plaque psoriasis. The US...

New antibacterial drug approved by FDA to treat complicated urinary tract infections for antimicrobial resistance

Nov 14, 2019: The U.S. Food and Drug Administration (FDA)  approved Shionogi’s Fetroja (cefiderocol), an antibacterial drug used for the...

Most Read

Eisai and Wren Therapeutics Enter Into Research Collaboration Agreement for Drug Discovery for Synucleinopathies

November 30, 2020: Eisai and Wren Therapeutics announced that the companies have entered into an exclusive research collaboration agreement aiming to advance...

AstraZeneca agreed to sell rights to Crestor to be divested to Grünenthal in Europe

December 01, 2020: AstraZeneca has agreed to sell the rights to Crestor (rosuvastatin) and associated medicines in over 30 countries in Europe, except the...

AstraZeneca’sForxiga approved in Japan for chronic heart failure

November 30, 2020: AstraZeneca’s Forxiga (dapagliflozin) has been approved in Japan for the treatment of patients with chronic heart failure (HF) who are receiving...

Moderna Announces the EC Approval for Initial 80 Million Doses of mRNA Vaccine Against COVID-19

November 25, 2020: "Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines...